Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-29T15:13:00.236Z Has data issue: false hasContentIssue false

4 - Hormone replacement therapy and breast cancer

Published online by Cambridge University Press:  06 January 2010

Zenon Rayter
Affiliation:
Bristol Royal Infirmary
Janine Mansi
Affiliation:
St George's Hospital Medical School, University of London
Get access

Summary

Introduction

The cessation of menstruation is termed the menopause, the median age of which is 51 years in the United Kingdom, whereas the climacteric (or perimenopause) is the transitional period leading up to this during which ovarian function ceases and symptoms of ovarian failure may become manifest. This usually predates the menopause by approximately two to three years in the majority of women. Ovarian failure arises as a result of a reduction in ovarian responsiveness to gonadotrophin stimulation combined with an exhaustion of viable oocytes. As oestradiol production is predominantly dependent on oocyte maturation with an increase in anovulatory cycles, serum levels subsequently fall, endometrial stimulation fails to occur and amenorrhoea results. The short and long-term sequelae of this decline in ovarian oestrogen production are summarized in Table 4.1.

Vasomotor symptoms and their psychological sequelae can severely impair a women's quality of life (Daly et al., 1993). Symptoms are experienced by 75% of climacteric and early postmenopausal women but are usually self-limiting, lasting two to three years, although they can be life-long in a minority of women (Belchetz, 1994). Vaginal dryness and the subsequent superficial dyspareunia experienced by a proportion of women may contribute to loss of libido. Coronary artery disease is the most common cause of morbidity and mortality in women in many countries including the United Kingdom (Office for National Statistics Population and Health Monitor, 1997) and is the most frequent non-neoplastic cause of death in node-negative breast cancer survivors (Rosen et al., 1993).

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×